CEPI has announced a new funding opportunity for the sourcing of sera from recovered patients with securely diagnosed Rift Valley Fever (RVF) disease.
The sourced material will be used to develop a RVF antibody standard to support and accelerate the development of vaccines against RVF.
The call seeks to facilitate CEPI’s strategic objective on vaccine development for RVF, one of the CEPI prioritized diseases with epidemic potential. The ultimate purpose of this call is that it will lead to the development of WHO/ECBS-endorsed International Antibody Standard for RVF.
Applicant organisations: This request for proposals is open worldwide to relevant entities that bring the relevant expertise and experience to address challenges within the scope of this call. Funding beneficiaries must be legal entities. CEPI may conduct due diligence reviews for feasibility verification, legal, business and financial compliance before awards are made.
- Applicants may submit their proposals as a single actor or as a consortium. CEPI may request multiple applicants to collaborate towards the end deliverables of this call.
- They seek applicants with already established activities in connection to diagnosis, treatment and care of RVF patients.
- Groups or organizations with the flexibility and capacity to set up their RVF-activity and do the sourcing of sera in connection to new and different outbreak–sites will be particularly appreciated.
For more information, visit CEPI.